Next-Gen Lyme Test
Lyme Disease
Development/ValidationActive
Key Facts
About Kephera Diagnostics
Kephera Diagnostics is a commercial-stage, private diagnostics company targeting significant unmet needs in infectious diseases and women's health. Its core strategy involves developing novel immunoassays, including point-of-care and ELISA formats, and offering them through its own certified clinical laboratory. The company has launched several first-to-market tests, including a blood-based diagnostic for endometriosis (EndomTest™) and comprehensive panels for parasitic infections like Chagas disease and liver fluke, supported in part by NIH grants. Kephera's model combines proprietary test development with a revenue-generating laboratory services business.
View full company profileTherapeutic Areas
Other Lyme Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| VLA15 | Valneva | Phase 3 |
| Lyme Disease and Coinfections Diagnostics | Fry Laboratories | Commercial |
| Lyme Disease Diagnostic | BlueArc Biosciences | Research/Proof-of-Concept |
| Lyme Disease Vaccine | CyanVac | Preclinical |
| Lyme Disease Diagnostic Personalization | Innatoss Laboratories | Research |